[1] Mohyeldin A, Lu H, Dalgar d C, et al. Erythropoietin signaling promotes vasiveness of human head and neck squamous cell carcinoma. Neoplasia, 2005, 7(5):537-543.
[2] Arcasoy MO, Amin K, Chou SC, et al. Erythropoietin and erythropoietin receptor expression in head and neck cancer:relationship to tumor hypoxia. Clin Cancer Res, 2005, 11(1):20-27.
[3] Arcasoy MO, Amin K, Volhner RT, et al. Erythropoietin and erythropoietin receptor expression in human prostate cancer. Mod Pathol, 2005, 18(3):421-430.
[4] Arcasoy MO, Amin K, Karayal AF, et al:Functional significance of erythropoietin reeeptor expression in breast cancer. Lab Invest, 2002, 82(7):911-918.
[5] Acs G. Zhang PJ, Rebbeck TR, et al. hnmunohistochemieal expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer, 2002, 95(5):969-981.
[6] Acs G, Xu X, Chu C, et al. Prognostic significanee of erythropoietin expression in human endometrial carcinoma. Cancer, 2004, 100(11):2376-2386.
[7] Acs G, Zhang PJ, McGrath CM, et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squaroous cell carcinoroa of the uterine cervix and its potential role in cervical carcinogenesis and tunror progression. Am J Pathol, 2003, 162(6):1789-1806.
[8] Batra S, Perehnan N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest, 2003, 83(10):1477-1487.
[9] Dagnon K, Pacary E, Commo F, et al. Expression of erythropoietin and erythropoietin receptor in non-small cell lung carcinomas. Clin Cancer Res, 2005, 11(3):993-999.
[10] Kumar SM Acs G, Fang D, et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol, 2005, 166(3):823-830.
[11] Winter SC, Shah KA, Campo L, et al. Relation of erythropoietin and erythropoietin receptor expression to hypoxia and anemia in head and neck squamous cell carcinoma. Clin Cancer Res, 2005, 11(21):7614-7620.
[12] Hale SA, Wong C, Lounsbury KM. Erythropoietin disrupts hypoxia-inducible factor signaling in ovarian cancer cells. Gynecol Oncol, 2006, 100(1):14-19.
[13] Lester RD, Jo M, Campana WM, et al. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J Biol Chem, 2005, 280(47):39273-39277.
[14] Hoogsteen IJ, Peeters WJ, Marres HA, et al. Erythropoietin receptor is not a surrogate marker for tumor hypoxia and does not correlate with survival in head and neck squamous cell carcinomas. Radiother Oncol, 2005, 76(2):213-218.
[15] Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of eportin alfa on hematologic parameter and quality of life in patients receiving nonplatinum chemotherapy:results of a randomized,double-blind, placebo-controlled clinical trials. J Clin Oncol, 2001, 19:1204-1214.
[16] Hanke M, Laszig R, Rube C, et al. Erthropoirtin to treat head and neck cancer patient with anemia undergoing radiotherapy:randomized,double-blind, placebo-controlled trial. Lancet, 2003, 362:1255-1260.
[17] Yasuda Y, Furida Y, Matsuo T, et al. Erthropoietin regulates tumor growth of human malignancies. Carciogenesis, 2003, 24:1021-1029.